Merck is Very Much a No Go - Recensione dipendente - Data Research Scientist presso Merck

1,0
28 feb 2016
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

A few good people remain. Company benefits are average or above, other than tuition reimbursement which now is inadequate to earn a MS.

Svantaggi

Very much a dying company. Astonishingly bad esprit de corps, much worse now than when I joined over a decade ago. In the past 3 years, 90% of R&D talent has left the company or transferred to other divisions. Upper management are trying to convert all the remaining R&D and IT tasks into mechanized processes to then outsource them (supposedly saving money). All corporate initiative focuses either on saving money or on promoting Keytruda.

Esplora altre recensioni su Merck

5,0
3 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

End of the year shutdown which includes paid time off

Svantaggi

The con for me at the time was that I had to relocate which wasn’t possible

4,0
2 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Over my tenure, I had the opportunity to work alongside highly talented and mission-driven colleagues dedicated to improving patient outcomes. The organization provided exposure to cross-functional collaboration, leadership development opportunities, and meaningful work supporting healthcare providers, patients, and community stakeholders. I appreciated the company's commitment to innovation, professional growth, and serving patients through scientific advancement.

Svantaggi

Like many large organizations, priorities and organizational structures evolved over time, which occasionally created uncertainty and changes in responsibilities. Decision-making processes could sometimes be complex due to the size of the organization, and navigating multiple layers of stakeholders occasionally impacted speed and execution.

Vedi recensioni per: Utile|Valutazione|Data|Tutto